Apnimed, Inc.
0 products tracked · names used in filings: Apnimed, Inc.
Upcoming milestones
Sun 28 Feb 2027🇺🇸 PDUFA datecompany-announcedin 106 days
AD109 (Oxnimbi): PDUFA target action date (obstructive sleep apnea in adults)
Apnimed, Inc. (APMD); aroxybutynin and atomoxetine; NDA; status: set; "Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi ™, and assigned a PDUFA target action date of February 28, 2027 • If approved, Oxnimbi has the potential to become the first oral pharmacologic therapy designed to address the neuromu"; filed 2026-09-08 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.